Supernus Pharmaceuticals Total Current Liabilities 2011-2024 | SUPN

Supernus Pharmaceuticals total current liabilities from 2011 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Supernus Pharmaceuticals Annual Total Current Liabilities
(Millions of US $)
2023 $290
2022 $688
2021 $315
2020 $245
2019 $161
2018 $161
2017 $123
2016 $81
2015 $57
2014 $28
2013 $26
2012 $23
2011 $19
2010 $
Supernus Pharmaceuticals Quarterly Total Current Liabilities
(Millions of US $)
2024-09-30 $292
2024-06-30 $309
2024-03-31 $315
2023-12-31 $290
2023-09-30 $288
2023-06-30 $253
2023-03-31 $732
2022-12-31 $688
2022-09-30 $726
2022-06-30 $736
2022-03-31 $285
2021-12-31 $315
2021-09-30 $235
2021-06-30 $283
2021-03-31 $241
2020-12-31 $245
2020-09-30 $300
2020-06-30 $269
2020-03-31 $168
2019-12-31 $161
2019-09-30 $150
2019-06-30 $144
2019-03-31 $152
2018-12-31 $161
2018-09-30 $138
2018-06-30 $104
2018-03-31 $119
2017-12-31 $123
2017-09-30 $105
2017-06-30 $86
2017-03-31 $82
2016-12-31 $81
2016-09-30 $72
2016-06-30 $68
2016-03-31 $56
2015-12-31 $57
2015-09-30 $44
2015-06-30 $37
2015-03-31 $28
2014-12-31 $28
2014-09-30 $22
2014-06-30 $19
2014-03-31 $27
2013-12-31 $26
2013-09-30 $25
2013-06-30 $16
2013-03-31 $27
2012-12-31 $23
2012-09-30 $25
2012-06-30 $22
2012-03-31 $20
2011-12-31 $19
2011-09-30
2011-06-30
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00